Ondine Biomedical has presented detailed results from its US Phase 2 BENEFIT-aPDT clinical trial to the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark.
The results indicate that patients who underwent Ondine's nasal photodisinfection prior to surgery experienced 66% fewer surgical site infections (SSIs) than the US national average.
Ondine's nasal photodisinfection also eliminated or significantly reduced Staphylococcus aureus, including MRSA, in 88% of carriers immediately after treatment.
Roger Andersen, Ondine’s VP, Regulatory and Medical Affairs said: "Our US Phase 2 trial met its primary endpoint last year, and these results confirm that a single, 5-minute treatment of nasal photodisinfection pre-surgically significantly reduces Staphylococcus aureus, a primary pathogen causing surgical site infections.
“These exciting results demonstrate the capabilities of this advanced infection prevention.
“Universal treatment with nasal photodisinfection before surgery could have a transformative effect on preventing SSIs and potentially lead to substantial cost savings for the US healthcare system."
Ondine is currently preparing for a US Phase 3 trial of its nasal photodisinfection, with further details to be announced later this year.